Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Pfizer brands
PF-184563
Другие языки:

    PF-184563

    Подписчиков: 0, рейтинг: 0
    PF-184563
    PF-184563.png
    Clinical data
    ATC code
    • none
    Pharmacokinetic data
    Bioavailability 34%
    Protein binding 69%
    Elimination half-life 1.8h
    Identifiers
    • 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene
    CAS Number
    ChemSpider
    ChEMBL
    Chemical and physical data
    Formula C21H23ClN6
    Molar mass 394.91 g·mol−1
    3D model (JSmol)
    • CN1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCN(CC4)C5=CC=CC=N5)C1
    • InChI=1S/C21H23ClN6/c1-26-13-16-12-17(22)5-6-18(16)28-20(14-26)24-25-21(28)15-7-10-27(11-8-15)19-4-2-3-9-23-19/h2-6,9,12,15H,7-8,10-11,13-14H2,1H3 ☒N
    • Key:LXHAZNJVVVBJIF-UHFFFAOYSA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor. The compound was discovered by Pfizer in its Sandwich, Kent research center, as a potential treatment for dysmenorrhoea, an indication for which V1a antagonists have shown efficacy.


    Новое сообщение